Compare LQDA & PFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LQDA | PFS |
|---|---|---|
| Founded | 2004 | 1839 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2020 | 2002 |
| Metric | LQDA | PFS |
|---|---|---|
| Price | $37.34 | $21.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $41.00 | $23.75 |
| AVG Volume (30 Days) | ★ 1.2M | 807.6K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 4.54% |
| EPS Growth | 51.81 | ★ 112.38 |
| EPS | N/A | ★ 2.23 |
| Revenue | ★ $158,320,000.00 | $73,109,000.00 |
| Revenue This Year | $265.61 | $0.42 |
| Revenue Next Year | $62.82 | $6.17 |
| P/E Ratio | ★ N/A | $9.49 |
| Revenue Growth | ★ 1031.18 | 7.06 |
| 52 Week Low | $11.26 | $14.34 |
| 52 Week High | $46.67 | $23.98 |
| Indicator | LQDA | PFS |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 55.52 |
| Support Level | $31.75 | $19.34 |
| Resistance Level | $39.19 | $23.98 |
| Average True Range (ATR) | 1.92 | 0.44 |
| MACD | 0.16 | 0.13 |
| Stochastic Oscillator | 68.76 | 87.04 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.